Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
March 20, 2020 16:01 ET
|
Forty Seven, Inc.
-- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML ---- Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and...
Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia
March 11, 2020 08:00 ET
|
Forty Seven, Inc.
MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV) and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) announced today that they have entered into a...
Forty Seven to Present at Upcoming Investor Conferences in March
February 25, 2020 08:00 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven to Present at Upcoming Investor Conferences in February
February 06, 2020 08:00 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight...
Forty Seven Announces 2020 Strategic Priorities and Expected Milestones
January 10, 2020 08:00 ET
|
Forty Seven, Inc.
-- Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 -- -- Updated Data from Ongoing Phase 1b...
Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares
December 16, 2019 16:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public...
Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock
December 11, 2019 22:32 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten...
Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock
December 11, 2019 16:01 ET
|
Forty Seven, Inc.
MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced that it has commenced an underwritten public...
Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation
December 09, 2019 10:00 ET
|
Forty Seven, Inc.
-- Expect to Initiate Phase 1 Clinical Trial in Healthy Volunteers in First Quarter of 2020 ---- Forty Seven to Host Investor Event and Webcast at 8:00 p.m. ET -- MENLO PARK, Calif., Dec. 09, 2019...
Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
December 09, 2019 07:00 ET
|
Forty Seven, Inc.
-- CR Rate of 50% and ORR of 92% Observed in Untreated Patients with Higher-Risk MDS ---- CR/CRi Rate of 55% and ORR of 64% Observed in Patients with Untreated AML Who are Ineligible for Induction...